...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients.
【24h】

Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients.

机译:肺移植受者中的蛋白质组闭塞性细支气管炎综合征风险监测。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Obliterative bronchiolitis poses a primary obstacle for long-term survival of lung transplant recipients and manifests clinically as bronchiolitis obliterans syndrome (BOS). Establishing a molecular level screening method to detect BOS-related proteome changes before its diagnosis by forced expiratory volume surrogate marker criteria was the main objective of this study. METHODS: Bronchoalveolar lavage was performed in 82 lung transplant recipients (48/34 with/without known BOS development) at different time points between 12 and 48 months after lung transplantation. A mass spectrometry-based method was devised to generate bronchoalveolar lavage fluid proteome profiles that were screened for BOS-specific alterations. Statistically significant marker peptides and proteins were identified and validated by in-gel digestion, tandem mass spectrometric sequencing, and quantitative immunoassays. RESULTS: Among the panel of statistically significant markers were Clara cell protein, calgranulin A, human neutrophil peptides, and the antimicrobial agent histatin. To assess their clinical relevance, a highly sensitive and specific classifier model was developed. Positive BOS classification by monitoring of seven polypeptides correlated strongly with a significant decrease in BOS-free time. Thus, it was possible to detect high-risk patients early on in the pathogenetic process. CONCLUSIONS: Monitoring the bronchoalveolar lavage fluid levels of seven polypeptides detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry allows a reliable prediction of early BOS using a Random Forest decision tree-based classifier model. The high accuracy of this robust model and its synergistic potential in combination with established forced expiratory volume-based diagnostics could make it an effective tool to supplement the current diagnostic regime after multicentric validation.
机译:背景:闭塞性细支气管炎是肺移植受者长期存活的主要障碍,临床表现为闭塞性细支气管炎综合征(BOS)。本研究的主要目的是建立一种分子水平筛选方法,以通过强制呼气量替代标志物标准在其诊断之前检测BOS相关蛋白质组的变化。方法:在肺移植后12至48个月的不同时间点,对82名肺移植受者(48/34伴/不伴BOS发生)进行了支气管肺泡灌洗。设计了一种基于质谱的方法来生成支气管肺泡灌洗液蛋白质组图谱,并针对BOS特异性变化进行筛选。通过凝胶内消化,串联质谱测序和定量免疫测定法鉴定并验证了具有统计意义的标志物肽和蛋白质。结果:具有统计学意义的标志物包括克拉拉细胞蛋白,钙粒蛋白A,人中性粒细胞肽和抗菌剂组蛋白。为了评估它们的临床相关性,开发了一种高度敏感和特定的分类器模型。通过监测七种多肽的阳性BOS分类与无BOS时间的显着减少密切相关。因此,有可能在发病过程中及早发现高危患者。结论:监测基质辅助激光解吸/电离飞行时间质谱检测到的七个多肽的支气管肺泡灌洗液水平,可以使用基于随机森林决策树的分类器模型可靠地预测早期BOS。此鲁棒模型的高精度及其协同潜力与已建立的基于强迫呼气的体积诊断相结合,可以使其成为有效的工具,以补充多中心验证后的当前诊断方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号